Drug Release from Gelsolin-Targeted Phase-Transition Nanoparticles Triggered by Low-Intensity Focused Ultrasound

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Current cancer therapies face limitations in targeting tumors and drug delivery.
• Early detection and treatment of tumor metastasis are crucial for effective clinical intervention.
• Nonspecific drug delivery in chemotherapy leads to severe side effects.

Purpose of the Study:

• To develop a novel nanoparticle system for targeted cancer imaging and therapy.
• To utilize gelsolin (GSN) monoclonal antibody as a targeting agent.
• To employ perfluorohexane (PFH) as a phase-transition agent for controlled drug release.

Main Methods:

• Co-encapsulation of PFH and doxorubicin (DOX) into poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs).
• Conjugation of GSN monoclonal antibody onto NP surface to create GSN-targeted phase transition polymer NPs (GSN-PLGA-PFH-DOX).
• Application of low-intensity focused ultrasound (LIFU) to trigger on-demand drug release.

Main Results:

• GSN-PLGA-PFH-DOX NPs demonstrated narrow size distribution and smooth surface.
• NPs specifically bound to Hca-F cells and enhanced ultrasound contrast.
• LIFU-induced drug release resulted in synergistic cytotoxic effects in GSN-overexpressing cells.

Conclusions:

• The developed GSN-PLGA-PFH-DOX NPs offer a promising strategy for imaging and chemotherapy.
• This approach targets both primary tumors and their metastases.
• The study highlights the potential of targeted, ultrasound-responsive nanoparticles in cancer treatment.